Evidence map›Paper›PMID 42187560›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.

Christine Simmons, Omar F Khan, Christine Brezden-Masley, David W Cescon, Anil Abraham Joy, Nathalie LeVasseur, Katarzyna J Jerzak, Karen A Gelmon, Sandeep Sehdev, Stephen Chia and 9 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Christine SimmonsBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0002-6571-4587
Omar F KhanArthur J.E. Child Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada.ORCID 0000-0003-4424-5360
Christine Brezden-MasleyMarvelle Koffler Breast Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.ORCID 0000-0002-4818-318X
David W CesconPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-1080-0998
Anil Abraham JoyCross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.ORCID 0000-0003-4201-8930
Nathalie LeVasseurBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0002-2581-4903
Katarzyna J JerzakSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Karen A GelmonBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0003-4111-2757
Sandeep SehdevThe Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0001-7434-2263
Stephen ChiaBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.
Marc WebsterArthur J.E. Child Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada.
Scott EdwardsDr. H. Bliss Murphy Cancer Center, Memorial University of Newfoundland, St. John's, NL A1B 3V6, Canada.
Aalok KumarBC Cancer-Surrey, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.
Jeffrey Q CaoArthur J.E. Child Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada.
Jean-François BoileauJewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Kara LaingDr. H. Bliss Murphy Cancer Center, Memorial University of Newfoundland, St. John's, NL A1B 3V6, Canada.
Nathaniel BouganimMcGill University Health Centre, McGill University, Montréal, QC H4A 3J1, Canada.
Mita MannaSaskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada.ORCID 0000-0003-4344-7913
On Behalf Of Patient Advocacy Breast Cancer Canada

Funding

Breast Cancer Canada SOW 10
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) has been associated with a poorer prognosis than other subtypes, due to its more aggressive behaviour. Since 2020, significant advances in locoregional and systemic therapy have improved outcomes for patients with TNBC, but the implementation of these treatments remains inconsistent across Canada. There is, therefore, a critical need for evidence-informed, consensus-driven guidance to support the integration of new therapies into practice. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), a pan-Canadian group of breast cancer specialists and Breast Cancer Canada, a patient advocacy organization, convened to develop national clinical consensus recommendations for the management of breast cancer. Through a selective literature review and modified Delphi process of national experts in the fields of medical oncology, radiation oncology, surgical oncology and pharmacy, REAL Alliance developed national consensus recommendations for the management of TNBC. The result is a set of 23 recommendations: four overall general recommendations, 11 in early-stage TNBC, and eight in metastatic TNBC. These recommendations are intended for oncology healthcare professionals, and are intended to guide evidence-informed, consistent care across Canada.

Indexed as

Triple Negative Breast NeoplasmsCanadaFemaleHumansNeoplasm Metastasisbreast cancerCanadian consensus recommendationsevidence-informedREAL AllianceTNBC

Identifiers

PMID42187560
PMCPMC13205814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.